DUBLIN--(BUSINESS WIRE)--The "PharmaPoint: Healthcare-Associated Gram-Negative Infections - Global Drug Forecast and Market Analysis to 2026" report has been added to ResearchAndMarkets.com's offering.
The report provides the overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
It is expected that the market will exceed $3.6B in sales by 2026, at a Compound Annual Growth Rate (CAGR) of 10.6% from 2016-2026. These sales are projected to originate predominantly from the US, followed by Germany and France. This growth will be dominated by the launch of multiple pipeline products, which will contribute a combined 73% of the sales in 2026.
The current antibiotic pipeline is dominated by derivatives of commonly used scaffolds and combinations of beta-lactam antibiotics with beta-lactamases. However, the early stage pipeline includes novel approaches for new scaffolds and alternative approaches to combat resistance in Gram-negative bacteria, although most are currently in pre-clinical development.
Bacterial infections represent a frequent occurrence in humans. Fortunately, a majority of these infections are successfully eliminated by the native and adaptive immune system. The majority of remaining infections that do require medical assistance can be addressed by physicians outside the hospital setting using a set of generic antibiotics commonly prescribed throughout the seven major markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan).
Global marketplace for healthcare-associated infections (HAIs) caused by Gram-negative bacteria-which, for the purpose of this report, consist of the catheter-associated urinary tract infections (CAUTI), central-line-associated bloodstream infections (CLABSI), hospital-associated pneumonia (HAP), ventilator-associated pneumonia (VAP), and surgical site infections (SSI) leading to intra-abdominal infections (IAI), and are caused by either Acinetobacter baumannii, Enterobacter spp, Escherichia coli, Klebsiella spp, or Pseudomonas aeruginosa was worth approximately US$1.3B in 2016.
Key Topics Covered:
1. List of Tables and Figures
2. Executive Summary
4. Disease Overview
6. Disease Management
7. Competitive Assessment
8. Unmet Needs Assessment and Opportunity Analysis
9. Pipeline Assessment
10. Current and Future Players
11. Market Outlook
- Merck& Co.
- The Medicines Company
- Shionogi & Co., Ltd.
- Tetraphase Pharmaceuticals Inc.
- MerLion Pharmaceuticals Pte., Ltd.
- Aridis Pharmaceuticals
- MedImmune LLC
- Wockhardt Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/bssls3/3_6_billion?w=4
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.